Skip to content
Login
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Login
Log In
Account Settings
Login
Log In
Account Settings
Login
Sign Up
Real Clinics. Real Patients. Real Oncology.
Home
/
Topics
/
Cancer Types
/
Breast Cancer
Home /
Breast Cancer
Breast Cancer
Breast Cancer
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
FDA Approvals
Emory Research Helps Lead to New FDA-Approved Treatment For Aggressive Breast Cancer
August 10, 2026
Recent Updates
Messino Cancer Centers Opens Second Asheville, NC, Clinic
July 14, 2026
In Your Practice
HER2 Heartbreak: Managing Trastuzumab Cardiotoxicity in Breast Cancer
Courtney Muche
, PharmD;
Matthew Mattila
, PharmD, BCPS, BCOP
April 16, 2026
Patient Populations
The Sandwich Generation: Managing the Rise of Early-Onset Cancer
April 1, 2026
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
FDA Approvals
Emory Research Helps Lead to New FDA-Approved Treatment For Aggressive Breast Cancer
August 10, 2026
Recent Updates
Messino Cancer Centers Opens Second Asheville, NC, Clinic
July 14, 2026
In Your Practice
HER2 Heartbreak: Managing Trastuzumab Cardiotoxicity in Breast Cancer
Courtney Muche
, PharmD;
Matthew Mattila
, PharmD, BCPS, BCOP
April 16, 2026
Patient Populations
The Sandwich Generation: Managing the Rise of Early-Onset Cancer
April 1, 2026
News & Insights
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
FDA Approvals
Emory Research Helps Lead to New FDA-Approved Treatment For Aggressive Breast Cancer
August 10, 2026
Recent Updates
Messino Cancer Centers Opens Second Asheville, NC, Clinic
July 14, 2026
In Your Practice
HER2 Heartbreak: Managing Trastuzumab Cardiotoxicity in Breast Cancer
Courtney Muche
, PharmD;
Matthew Mattila
, PharmD, BCPS, BCOP
April 16, 2026
Patient Populations
The Sandwich Generation: Managing the Rise of Early-Onset Cancer
April 1, 2026
Podcasts
No results were found
What are you looking for?
Search
Search
POPULAR SEARCHES
Adjuvant Therapy
Biomarker Testing
Bladder Cancer
Blood-Based Tests
